

*Lilly***Fax**Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

Legal Department - Patent Division

To: Examiner F. T. MoezieCompany: USPTO
Fax: 9-1-703-746-5101
Phone:
Date: August 8, 2001From: Mark J. Stewart, Ph.D.
Fax: 317-276-5172
Phone: 317-276-0280
Total Pages: 8

Applicants : Hermeling, Ronald N., *et al.*)
Serial No. : 09/209,799)
Filed : December 11, 1998) Group Art Unit:
For : Glucagon-Like Peptide-1) 1653
Crystals) Examiner:
Docket No. : X-10242) F. Moezie

*Official - Enter
F. M. 8/8/01***Privileged and Confidential Communication**

If there are any transmittal problems please call: (317) 277-8827.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

G

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Cynthia Craft	
Type or print name of person signing certification	
<i>Cynthia Craft</i> Signature	August 8, 2001 Date

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: Hermeling, Ronald N., et al.)	
Serial No.	: 09/209,799)	
Filed	: December 11, 1998)	Group Art Unit:
)	1653
For	: Glucagon-Like Peptide-1)	Examiner:
	Crystals)	F. Moezie
Docket No.	: X-10242)	

AMENDMENT AFTER FINAL REJECTION
UNDER 37 C.F.R. 1.116

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

OFFICIAL - ENTER
F.M. 8/8/01

Per a phone conversation with the Examiner and Applicant's attorney on Monday, August 6, 2001, Applicants respectfully request that the Examiner enter the following amendments which the Examiner has indicated place the application in condition for allowance.

Claims 33 through 40, 42, and 75 through 76 are currently pending in the present application. The amendment presented below cancels claim 36, amends currently pending claims 33-35, 37-40, and 75, and adds new claims 77 through 79. Zinc and ammonium sulfate are now presented in separate claims. Ammonium sulfate is specified in new claims 77 through 79.

Please amend the Application as follows:

Cancel claim 36. Add new Claims 77 through 79.

G